2022-502319-12-00招募中1 期
A study to learn how safe the study treatment BAY3401016 is, how it affects the body and how it moves into, through, and out of the body when a single amount is given to healthy male participants
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Bayer AG
- 入组人数
- 126
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Therapeutic Area Head
Scientific
Bayer AG
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Phase III randomised study of BAY 43-9006 in patients with unresectable and/or metastatic renal cell cancerACTRN12605000643673Bayer Australia Ltd884
进行中（未招募）
1 期
clinical study to evaluate the efficacy and safety of a new drug (Bardoxolone methyl) in the treatment of subjects with Alport syndromeMedDRA version: 20.0Level: PTClassification code 10001843Term: Alport's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersAlport SyndromeEUCTR2016-004395-22-FRReata Pharmaceuticals, Inc.187
进行中（未招募）
1 期
clinical study to evaluate the efficacy and safety of a new drug (Bardoxolone methyl) in the treatment of subjects with Alport syndromeMedDRA version: 20.0Level: PTClassification code 10001843Term: Alport's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersAlport SyndromeEUCTR2016-004395-22-DEReata Pharmaceuticals, Inc.180
已完成
不适用
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport SyndromeAlport SyndromeJPRN-UMIN000032448Reata Pharmaceuticals, Inc187
进行中（未招募）
1 期
clinical study to evaluate the efficacy and safety of a new drug (Bardoxolone methyl) in the treatment of subjects with Alport syndromeMedDRA version: 20.0Level: PTClassification code 10001843Term: Alport's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersAlport SyndromeEUCTR2016-004395-22-ESReata Pharmaceuticals, Inc.187